Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Drugs In Development, 2022, provides an overview of the Anal Cancer (Oncology) pipeline landscape.
Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 36, 27, 2 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anal Cancer - Overview
Anal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anal Cancer - Companies Involved in Therapeutics Development
Anal Cancer - Drug Profiles
Anal Cancer - Dormant Projects
Anal Cancer - Discontinued Products
Anal Cancer - Product Development Milestones
Featured News & Press Releases
Dec 06, 2021: PDS Biotech provides recruitment update for National Cancer Institute-Led phase 2 clinical trial of PDS0101-based combination
Oct 15, 2021: Zynyz: Withdrawal of the marketing authorisation application
Jul 23, 2021: Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal (SCAC)
Jun 24, 2021: Incyte announces outcome of FDA Oncologic Drugs Advisory Committee (ODAC) meeting reviewing retifanlimab as a treatment for patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Jun 24, 2021: Transgene: First patient enrolled in expanded phase II clinical trial of TG4001 + avelumab Vs avelumab alone in patients With HPV16-positive anogenital cancers
Mar 10, 2021: Transgene expands phase II clinical trial of therapeutic vaccine TG4001 in combination with Avelumab versus Avelumab monotherapy in patients with HPV16-positive anogenital cancers
Feb 26, 2021: Incyte announces the validation by the European Medicines Agency of its marketing authorization application for retifanlimab as a treatment for patients with squamous cell anal carcinoma (SCAC)
Nov 30, 2020: MacroGenics announces achievement of $25 million in milestones related to retifanlimab collaboration with Incyte
Apr 08, 2019: Inovio achieves third cancer indication milestone for MEDI0457 phase 2 development
Apr 03, 2019: MacroGenics reports presentation of data on MGA-012 at the AACR Annual Meeting 2019
Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer
Nov 08, 2016: Dr. Shepard, CMO Of PDS Biotechnology, To Present PDS0101 Phase I/IIA Clinical Data At The Society For Immunotherapy Of Cancer Meeting On November 11, 2016
Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
Dec 07, 2015: ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anal Cancer - Pipeline by Antiva Biosciences Inc, 2022
Anal Cancer - Pipeline by AstraZeneca Plc, 2022
Anal Cancer - Pipeline by Beijing Corregene Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Bicara Therapeutics Inc, 2022
Anal Cancer - Pipeline by Biomimetix JV LLC, 2022
Anal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Anal Cancer - Pipeline by Cue Biopharma Inc, 2022
Anal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
Anal Cancer - Pipeline by Eisai Co Ltd, 2022
Anal Cancer - Pipeline by Eli Lilly and Co, 2022
Anal Cancer - Pipeline by EpimAb Biotherapeutics Inc, 2022
Anal Cancer - Pipeline by eTheRNA Immunotherapies NV, 2022
Anal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Anal Cancer - Pipeline by Fujifilm Holdings Corp, 2022
Anal Cancer - Pipeline by Genexine Inc, 2022
Anal Cancer - Pipeline by Genocea Biosciences Inc, 2022
Anal Cancer - Pipeline by Gilead Sciences Inc, 2022
Anal Cancer - Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
Anal Cancer - Pipeline by HaloVax, 2022
Anal Cancer - Pipeline by Hookipa Pharma Inc, 2022
Anal Cancer - Pipeline by IMV Inc, 2022
Anal Cancer - Pipeline by Incyte Corp, 2022
Anal Cancer - Pipeline by Invectys SA, 2022
Anal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
Anal Cancer - Pipeline by Merck & Co Inc, 2022
Anal Cancer - Pipeline by Merck KGaA, 2022
Anal Cancer - Pipeline by Mereo Biopharma Group Plc, 2022
Anal Cancer - Pipeline by Molecular Partners AG, 2022
Anal Cancer - Pipeline by Nektar Therapeutics, 2022
Anal Cancer - Pipeline by Novartis AG, 2022
Anal Cancer - Pipeline by Oncolytics Biotech Inc, 2022
Anal Cancer - Pipeline by Onconova Therapeutics Inc, 2022
Anal Cancer - Pipeline by Oncorus Inc, 2022
Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Anal Cancer - Pipeline by PDS Biotechnology Corp, 2022
Anal Cancer - Pipeline by Precigen Inc, 2022
Anal Cancer - Pipeline by Privo Technologies Inc, 2022
Anal Cancer - Pipeline by Repertoire Immune Medicines Inc, 2022
Anal Cancer - Pipeline by Rubius Therapeutics Inc, 2022
Anal Cancer - Pipeline by Sanofi, 2022
Anal Cancer - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Anal Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Anal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Shattuck Labs Inc, 2022
Anal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
Anal Cancer - Pipeline by SOTIO Biotech AS, 2022
Anal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Anal Cancer - Pipeline by Statera Biopharma Inc, 2022
Anal Cancer - Pipeline by Transgene SA, 2022
Anal Cancer - Pipeline by Treadwell Therapeutics Inc, 2022
Anal Cancer - Pipeline by TScan Therapeutics Inc, 2022
Anal Cancer - Pipeline by Turnstone Biologics Inc, 2022
Anal Cancer - Pipeline by Virion Therapeutics LLC, 2022
Anal Cancer - Pipeline by Xencor Inc, 2022
Anal Cancer - Pipeline by Y-Biologics Inc, 2022
Anal Cancer - Pipeline by Zymeworks Inc, 2022
Anal Cancer - Dormant Projects, 2022
Anal Cancer - Dormant Projects, 2022 (Contd..1)
Anal Cancer - Discontinued Products, 2022
List of Figures
Number of Products under Development for Anal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
